These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 21445612)

  • 1. A Bayesian approach for the estimation of patient compliance based on the last sampling information.
    Barrière O; Li J; Nekka F
    J Pharmacokinet Pharmacodyn; 2011 Jun; 38(3):333-51. PubMed ID: 21445612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels.
    Gotta V; Widmer N; Montemurro M; Leyvraz S; Haouala A; Decosterd LA; Csajka C; Buclin T
    Clin Pharmacokinet; 2012 Mar; 51(3):187-201. PubMed ID: 22339450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimation of population pharmacokinetic parameters in the presence of non-compliance.
    Mu S; Ludden TM
    J Pharmacokinet Pharmacodyn; 2003 Feb; 30(1):53-81. PubMed ID: 12800807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia.
    Golabchifar AA; Rezaee S; Ghavamzadeh A; Alimoghaddam K; Dinan NM; Rouini MR
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):85-93. PubMed ID: 24817601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing?
    von Mehren M; Widmer N
    Cancer Treat Rev; 2011 Jun; 37(4):291-9. PubMed ID: 21078547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetically based estimation of patient compliance with oral anticancer chemotherapies: in silico evaluation.
    Hénin E; Tod M; Trillet-Lenoir V; Rioufol C; Tranchand B; Girard P
    Clin Pharmacokinet; 2009; 48(6):359-69. PubMed ID: 19650675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group.
    Judson I; Ma P; Peng B; Verweij J; Racine A; di Paola ED; van Glabbeke M; Dimitrijevic S; Scurr M; Dumez H; van Oosterom A
    Cancer Chemother Pharmacol; 2005 Apr; 55(4):379-386. PubMed ID: 15592836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients.
    Peng B; Hayes M; Resta D; Racine-Poon A; Druker BJ; Talpaz M; Sawyers CL; Rosamilia M; Ford J; Lloyd P; Capdeville R
    J Clin Oncol; 2004 Mar; 22(5):935-42. PubMed ID: 14990650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-dose, randomized crossover comparisons of different-strength imatinib mesylate formulations in healthy Korean male subjects.
    Kim KA; Park SJ; Kim C; Park JY
    Clin Ther; 2013 Oct; 35(10):1595-602. PubMed ID: 24060561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic drug monitoring of imatinib for chronic myeloid leukemia patients in the chronic phase.
    Takahashi N; Miura M
    Pharmacology; 2011; 87(5-6):241-8. PubMed ID: 21474977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics interaction between imatinib and genistein in rats.
    Wang Z; Wang L; Xia MM; Sun W; Huang CK; Cui X; Hu GX; Lian QQ; Wang ZS
    Biomed Res Int; 2015; 2015():368976. PubMed ID: 25629045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib mesylate in the treatment of gastrointestinal stromal tumour.
    Steinert DM; McAuliffe JC; Trent JC
    Expert Opin Pharmacother; 2005 Jan; 6(1):105-13. PubMed ID: 15709888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy.
    Wilhelm AJ; de Graaf P; Veldkamp AI; Janssen JJ; Huijgens PC; Swart EL
    Br J Clin Pharmacol; 2012 Apr; 73(4):553-63. PubMed ID: 21988410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.
    Gibbons J; Egorin MJ; Ramanathan RK; Fu P; Mulkerin DL; Shibata S; Takimoto CH; Mani S; LoRusso PA; Grem JL; Pavlick A; Lenz HJ; Flick SM; Reynolds S; Lagattuta TF; Parise RA; Wang Y; Murgo AJ; Ivy SP; Remick SC;
    J Clin Oncol; 2008 Feb; 26(4):570-6. PubMed ID: 18235116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib.
    Cortes J; Jabbour E; Daley GQ; O'Brien S; Verstovsek S; Ferrajoli A; Koller C; Zhu Y; Statkevich P; Kantarjian H
    Cancer; 2007 Sep; 110(6):1295-302. PubMed ID: 17623836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic drug monitoring in CML patients on imatinib.
    Blasdel C; Egorin MJ; Lagattuta TF; Druker BJ; Deininger MW
    Blood; 2007 Sep; 110(5):1699-701; author reply 1701. PubMed ID: 17712052
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer.
    Nabhan C; Villines D; Valdez TV; Tolzien K; Lestingi TM; Bitran JD; Christner SM; Egorin MJ; Beumer JH
    Br J Cancer; 2012 Aug; 107(4):592-7. PubMed ID: 22805325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic modeling and development of Bayesian estimators in kidney transplant patients receiving the tacrolimus once-daily formulation.
    Saint-Marcoux F; Debord J; Undre N; Rousseau A; Marquet P
    Ther Drug Monit; 2010 Apr; 32(2):129-35. PubMed ID: 20110850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suicide attempt with an overdose of imatinib.
    Iketani O; Ueda T; Yamayoshi Y; Yamaguchi M; Kawamura S; Okamoto S
    Br J Clin Pharmacol; 2012 Nov; 74(5):890-2. PubMed ID: 22435728
    [No Abstract]   [Full Text] [Related]  

  • 20. Imatinib treatment in chronic myelogenous leukemia: What have we learned so far?
    Breccia M; Efficace F; Alimena G
    Cancer Lett; 2011 Jan; 300(2):115-21. PubMed ID: 21074936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.